Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $42.8 million.

  • Agios Pharmaceuticals' Share-based Compensation rose 11.05% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.3 million, marking a year-over-year increase of 7.81%. This contributed to the annual value of $42.8 million for FY2024, which is 4.29% down from last year.
  • As of FY2024, Agios Pharmaceuticals' Share-based Compensation stood at $42.8 million, which was down 4.29% from $44.8 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Share-based Compensation high stood at $61.6 million for FY2020, and its period low was $42.8 million during FY2024.
  • Its 3-year average for Share-based Compensation is $45.6 million, with a median of $44.8 million in 2023.
  • Per our database at Business Quant, Agios Pharmaceuticals' Share-based Compensation climbed by 6.12% in 2020 and then dropped by 13.14% in 2021.
  • Agios Pharmaceuticals' Share-based Compensation (Yearly) stood at $61.6 million in 2020, then dropped by 13.14% to $53.5 million in 2021, then dropped by 7.87% to $49.3 million in 2022, then decreased by 9.19% to $44.8 million in 2023, then declined by 4.29% to $42.8 million in 2024.